{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}]}],"title":"Improved"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}]}],"title":"No Change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"}]}],"title":"Worsened"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"8"}]}],"title":"Non-evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"Best HRQoL response using the total FACT-O endpoint. Improvement was defined as a change from baseline of greater than or equal to +9.","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable for FACT-O at baseline","reportingStatus":"POSTED","timeFrame":"At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Best QoL Response for Total Functional Analysis of Cancer Therapy - Ovarian (FACT-O)","type":"SECONDARY","unitOfMeasure":"Participants"}